Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Next Previous
Trial Profile

PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms PALLAS

    • Most Recent Events

    • 09 Dec 2023 Results assessing Racial and Ethnic Differences in Clinical Outcomes in patients (pts) with early-stage HR+HER2- breast cancer treated with or without adjuvant palbociclib ,presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2023 Results evaluating clinical and demographic variables associated with HER2 expression, presented at the 46th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2023 Results of exploratory analysis assessing whether concomitant use of PPIs could have affected clinical outcomes in patients treated with pal, presented at the 46th Annual San Antonio Breast Cancer Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top